<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="infections. There are currently approximately 90 drugs approved for the" exact="treatment" post="of human viral infections. As resistance toward available antiviral"/>
 <result pre="the expected results [1,4,5]. For many viral infections, only symptomatic" exact="treatment" post="is indicated, while it is expected the immune system"/>
 <result pre="are high-virulence viruses that cause serious viral infections where antiviral" exact="treatment" post="is essential for patient survival. Although great efforts have"/>
 <result pre="there are approximately 90 drugs approved for use in the" exact="treatment" post="of nine human viral infections caused by human immunodeficiency"/>
 <result pre="were reported in 2016 [45], with the highest incidence of" exact="infection" post="in sub-Saharan Africa. In the Third World, HIV infection"/>
 <result pre="of infection in sub-Saharan Africa. In the Third World, HIV" exact="infection" post="coupled with tropical diseases, malaria and tuberculosis causes a"/>
 <result pre="organic compounds have been developed as drug candidates for the" exact="treatment" post="of AIDS targeting one or more stages of the"/>
 <result pre="with nucleoside or non-nucleoside structures are currently used in AIDS" exact="treatment" post="[48]. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine,"/>
 <result pre="cytotoxicity, NNRTIs have gained an increasingly important role in HIV" exact="infection" post="therapy [49]. Five drugs in the class of NNRTIs"/>
 <result pre="in the class of NNRTIs have been approved for the" exact="treatment" post="of HIV infection: nevirapine, delavirdine and efavirenz as the"/>
 <result pre="August 2018, FDA approved both applications of doravirine for AIDS" exact="treatment" post="as Pifeltro tablets (doravirine 100 mg) and Delstrigo tablets"/>
 <result pre="capable of controlling viremia and reducing mortality [61]. However, long-term" exact="treatment" post="with antiretroviral agents can lead to drug resistance due"/>
 <result pre="that address the limitations of currently available agents for the" exact="treatment" post="of HIV infection [46,59]. As a bioisostere of pyrimidine,"/>
 <result pre="limitations of currently available agents for the treatment of HIV" exact="infection" post="[46,59]. As a bioisostere of pyrimidine, a nucleoside component"/>
 <result pre="macrophages and microglia, which are the main targets of HIV-1" exact="infection" post="in the brain. When infected with HIV-1, macrophages and"/>
 <result pre="process and can provide a new therapeutic target for the" exact="treatment" post="of neurocognitive disorders associated with HIV infection [71,72,78]. In"/>
 <result pre="target for the treatment of neurocognitive disorders associated with HIV" exact="infection" post="[71,72,78]. In connection with these results, a large number"/>
 <result pre="acid virus that infects people of all ages [79,80]. HCMV" exact="infection" post="can be acquired through horizontal and vertical transmission. HCMV"/>
 <result pre="and vertical transmission. HCMV spreads from infected people through direct" exact="contact" post="with body fluids that carry the virus, such as"/>
 <result pre="or transmission via blood transfusion, is also possible [79,80]. Blood" exact="tests" post="indicate that 60%–90% of the adult population experienced HCMV"/>
 <result pre="tests indicate that 60%–90% of the adult population experienced HCMV" exact="infection" post="at some time during their life [81]. Although most"/>
 <result pre="organ transplant recipients) can develop severe illnesses that require medical" exact="treatment" post="[79]. HCMV is able to remain latent in several"/>
 <result pre="immune system suppression [79,82]. The first-line drugs recommended for the" exact="treatment" post="of HCMV infection are intravenous ganciclovir or orally administered"/>
 <result pre="[79,82]. The first-line drugs recommended for the treatment of HCMV" exact="infection" post="are intravenous ganciclovir or orally administered valganciclovir [83]. Although"/>
 <result pre="Both drugs cause a high level of nephrotoxicity that limits" exact="treatment" post="[83]. Novel 2-amino-1,3,4-thiadiazole derivatives with antiviral activity against HCMV"/>
 <result pre="different impact on human health [97]. While HAV or HEV" exact="infection" post="is usually mild, with most people recovering quickly and"/>
 <result pre="is usually mild, with most people recovering quickly and completely," exact="infection" post="with HBV, HCV or HDV often leads to chronic"/>
 <result pre="There are about 15 million people living with chronic HBV" exact="infection" post="and about 14 million with HCV infection in the"/>
 <result pre="with chronic HBV infection and about 14 million with HCV" exact="infection" post="in the European Region [97]. Safe and effective vaccines"/>
 <result pre="[97]. Safe and effective vaccines for the prevention of HBV" exact="infection" post="have been available since the 1990s. These vaccines also"/>
 <result pre="vaccine became available in the 1990s. In these cases, drug" exact="treatment" post="is the only option [98]. Several nucleoside and non-nucleoside"/>
 <result pre="the costs of antiviral drugs for chronic hepatitis, access to" exact="treatment" post="is a major obstacle in many countries and finding"/>
 <result pre="also tested by the cell viability method (MTT assay). Preliminary" exact="screening" post="indicated high inhibitory activity against HBV with an IC50"/>
 <result pre="did not exhibit antiviral activity at subtoxic concentrations, in vitro" exact="tests" post="showed antiviral activity for thiourea derivatives 47 and 48,"/>
 <result pre="amaranticolor. The ability of derivatives 61–64 to control the viral" exact="infection" post="of Chenopodium amaranticolor leaves was studied at two concentrations:"/>
 <result pre="100 ppm. Generally, the compounds showed good rates of viral" exact="infection" post="control at 1000 ppm. The best results were observed"/>
 <result pre="and development of new medicines as an alternative to the" exact="treatment" post="of viral infections. Funding This research received no external"/>
 <result pre="targeted pharmacological scaffoldEur. J. Med. Chem.20159215617710.1016/j.ejmech.2014.12.03525553540 27.SerbanG.Future prospects in the" exact="treatment" post="of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasisMolecules201924155710.3390/molecules2408155731010226 28.LiY.GengJ.LiuY.YuS.ZhaoG.Thiadiazole—A promising structure"/>
 <result pre="trialJ. Acquir. Immune Defic. Syndr.20136217117910.1097/QAI.0b013e31827a2ba223328090 60.PlattenM.FatkenheuerG.Lersavirine—a new drug for HIV" exact="infection" post="therapyExpert. Opin. Investig. Drugs2013221687169410.1517/13543784.2013.846325 61.SacksD.LedwabaJ.MorrisL.HuntG.M.Rapid detection of common HIV-1"/>
 <result pre="new drug for HIV infection therapyExpert. Opin. Investig. Drugs2013221687169410.1517/13543784.2013.846325 61.SacksD.LedwabaJ.MorrisL.HuntG.M.Rapid" exact="detection" post="of common HIV-1 drug resistance mutations by use of"/>
 <result pre="Neurochem.200710253954910.1111/j.1471-4159.2007.04594.x17596215 79.BabayoA.ThairuY.NasirI.A.BabaM.M.Serological evidence and sociodemographic risk factors of recent cytomegalovirus" exact="infection" post="in pregnant women attending a tertiary hospital in Maiduguri,"/>
 <result pre="An update of its use in the prevention of cytomegalovirus" exact="infection" post="and disease in transplant recipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 85.SakamotoH.HiranoM.NoseK.UenoS.OkiT.SugimotoK.NishiokaT.KusunokiS.NakamuraY.A case of severe"/>
 <result pre="of severe ganciclovir-induced encephalopathyCase Rep. Neurol.2013518318610.1159/00035563824403897 86.ThaisrivongsS.TurnerS.R.1,3,4-Thiadiazoles useful for the" exact="treatment" post="of CMV infectionsUS Patent6,150,3852000 87.collab: World Health OrganizationBattle against"/>
 <result pre="treatmentsAvailable online: https://www.fda.gov/patients/hepatitis-b-c/ hepatitis-b-and-c-treatments(accessed on 23 January 2020) 100.KurkelaS.RattiO.HuhtamoE.UzcateguiN.NuortiJ.P.LaakkonenJ.ManniT.HelleP.VaheriA.VapalahtiO.Sindbis virus" exact="infection" post="in resident birds, migratory birds, and humans, FinlandEmerg. Infect."/>
</results>
